Tanibirumab

Drug Profile

Tanibirumab

Alternative Names: Anti-KDR mAb - PharmAbcine; SSS-23; TTAC-0001

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator PharmAbcine
  • Developer 3SBio; PharmAbcine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Solid tumours
  • Preclinical Cancer; Choroidal neovascularisation

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase II trial in glioblastoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 19 Sep 2016 Tanibirumab is has completed a phase I trial for Solid tumours and is still in preclinical development for Choroidal neovascularisation in South Korea
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top